fbpx
QQQ
-1.88
286.62
-0.66%
DIA
-3.08
286.41
-1.09%
SPY
-3.16
348.78
-0.91%
TLT
+ 1.03
156.98
+ 0.65%
GLD
+ 0.04
178.62
+ 0.02%

Mind Medicine CEO Calls Compass IPO: A 'Clear Bellwether' For Psychedelic Space

September 19, 2020 9:11 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

On Friday, UK-based mental health care company Compass Pathways (NASDAQ:CMPS) announced it has begun trading on NASDAQ under the symbol CMPS.

This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.

JR Rahn, CEO of psychedelics drug development company Mind Medicine Inc. (NEO:MMED) (OTCQB:MMEDF), told us that Compass has an extremely high calibre team focused on serious drug development through the FDA pathway.

Mind Medicine was the first psychedelic company to go public in Canada in March of this year. 

“The immense success of the Compass IPO is a clear bellwether for the growing psychedelic medicine industry," said Rahn. "A 70% rise on the first day of trading is a clear vote of confidence for a new asset class of medicines from Wall Street."

Compass had anticipated the IPO earlier this month, when it announced filing its preliminary prospectus. The company is offering 7.5 million shares at a price of $17 per share, with total gross proceeds amounting to $127.5 million. 

The initial share price of the IPO was upsized on Friday from an expected $14 to $16, due to high demand. 

Price closed at $29 per share on Friday, marking a 70% daily increase.

The company stated they expect the offering to close on or around Tuesday, September 22.

An Anticipated IPO

Compass’ IPO was one of the most expected news in the psychedelics capital markets.

The company is one of the leading for-profit entities in the field of clinical research and product development of psychedelic compounds.

Today, Compass is focusing on the research of the psychedelic psilocybin in the treatment of treatment-resistant depression, with a proprietary formulation of synthetic psilocybin called COMP360.

Compass is conducting a psilocybin therapy clinical trial in 20 sites across nine countries in Europe and North America, which is at Phase 2. The company was granted Breakthrough Therapy designation for its psilocybin research by the FDA in 2018.

The study is being financed by a Series B round which closed in April for $80 million.

Compass is part of the portfolio of ATAI Life Sciences, an investment firm focused on  psychedelics and mental health. Peter Thiel, an early Facebook investor and co-founder of PayPal is among its largest shareholders, with 7.54% share in the company.

Given SEC regulations, Compass was unable to offer comments on the IPO.


Related Articles

Psyched: Cybin Raises CA$45M, Numinus Harvests Legal Mushrooms, Toadstool Enters Psychedelic Space

Cybin Raises CA$45 Million and Heads Towards NEO Exchange read more

4 Lessons The Emerging Psychedelics Industry Can Learn from The Cannabis Boom

By Evan Nison, NisonCo PR. read more

3 Key Leadership Traits For Disruptive Psychedelic Drug Development

This article was originally published on Microdose Psychedelic Insights, and appears here with permission. read more

You Are Not Alone: Psychedelic Therapy And Mental Health Awareness

This article was originally published on Microdose Psychedelic Insights, and appears here with permission. “The humanity we all share is more important than the mental illness we may not.”  Elyn R. Saks read more

'Psyched': Study Finds MDMA More Cost-Effective Than Traditional PTSD Treatments, Pharmather Goes Public

MDMA-assisted psychotherapy would result significantly more cost-effective than current available treatment options for post-traumatic stress disorder, according to a study distributed by the Multidisciplinary Association for Psychedelic Studies.  read more